Latest Healthcare News

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

Wellnex Life Limited announces the resignation of CEO Zack Bozinovski, who will remain with the company until April 2026, while a $2.3 million loan repayment schedule is negotiated.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

CONNEQT Health reports robust sales momentum for its CONNEQT Pulse arterial health monitor, with quarterly sales growth exceeding 50% and a fresh order for 10,000 units to meet rising demand.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Ramsay Health Care announces a fully franked ordinary distribution of AUD 2.9642 per security on its perpetual preference shares, reflecting a steady income stream for investors. The payment is scheduled for April 2026, subject to board and external approvals.